RNAZ Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Transcode Therapeutics Inc (RNAZ) is not a strong buy for a beginner, long-term investor at this time. The lack of significant positive catalysts, weak financial performance, and neutral trading sentiment suggest that it is better to hold off on investing in this stock currently.
The stock's MACD is below 0 and negatively contracting, indicating bearish momentum. RSI is neutral at 58.45, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). The pre-market price is $10, slightly above the pivot level of $9.601, with resistance at $10.354 and $10.819.
NULL identified. No recent news or significant insider/hedge fund activity.
Weak financial performance with negative EPS and net income. No recent congress trading data or significant trading trends.
In Q3 2025, revenue remained at $0 with no YoY growth. Net income improved YoY but remains negative at -$4,856,051. EPS dropped significantly by -96.02% YoY to -5.82, indicating poor profitability.
No data available for analyst ratings or price target changes.
